Belfast · Northern Ireland
TheBELFAST HERALDLocal knowledge. National perspective.
Retrospective archiveHistorical reports were compiled from linked contemporaneous sources. Dates refer to the events covered.How the archive works
HealthPremium archive

Phase-III trials of the Covaxin vaccine from India's Bharat Biotech showed a 65.2% efficacy against the Delta variant, a 77.8% efficacy against symptomatic COVID-19

Phase-III trials of the Covaxin vaccine from India's Bharat Biotech showed a 65.2% efficacy against the Delta variant, a 77.8% efficacy against symptomatic COVID-19, and a 93.4% efficacy against severe COVID-19.

By Belfast Herald Newsdesk1 min read

Herald Premium Archive

This report is for subscribers

Sign in or choose a plan to read this report and the complete Premium retrospective archive.

HealthPhase-III trials of the Covaxin vaccine from India's Bharat Biotech showed a 65.2% efficacy against the Delta variant, a 77.8% efficacy against symptomatic COVID-19

Phase-III trials of the Covaxin vaccine from India's Bharat Biotech showed a 65.2% efficacy against the Delta variant, a 77.8% efficacy against symptomatic COVID-19, and a 93.4% efficacy against severe COVID-19.

View Premium plansBrowse free archive reports